NCT02633189

Study Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

A Randomized Open-label Phase 3 Trial Comparing Bevacizumab + Erlotinib vs Erlotinib Alone as First Line Treatment of Patients With EGFR Mutated Advanced Non Squamous Non Small Cell Lung Cancer

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: National Cancer Institute, Naples · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test whether the combination of bevacizumab and erlotinib can prolong progression free survival as compared with erlotinib alone as first-line treatment in patients with non small cell lung cancer (NSCLC) with activating mutation of EGFR.

Detailed description

The co-primary objectives are to assess investigator-assess, and blinded independent centrally-reviewed progression-free survival .

Conditions

• Non-squamous Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Erlotinib	given orally 150 mg daily
DRUG	Bevacizumab	15 mg/kg intravenously every 21 days.

Timeline

• Start date: 2016-04-01
• Primary completion: 2023-12-01
• Completion: 2024-07-01
• First posted: 2015-12-17
• Last updated: 2023-03-24

Locations

55 sites across 1 country: Italy